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Abstract
The pathogenesis of glaucoma involves numerous intracellular mechanisms including the purinergic system contribution. Furthermore,
the presence and release of nucleotides and dinucleotides during the glaucomatous damage and the maintenance of degradation
machinery through ecto-nucleotidase activity are participating in the modulation of the suitable extracellular complex balance. The
aim of this study was to investigate the levels of diadenosine tetraphosphate (Ap4A) and the pattern of ecto-nucleotidase activity
expression in glaucomatous retinas during the progress the pathology. Ap4A levels were analyzed by HPLC in glaucomatous retinas
from the DBA/2J mice at 3, 9, 15, and 23 months of age. For that, retinas were dissected as flattened whole-mounts and stimulated in
Ringer buffer with or without 59 mM KCl. NPP1 expression was analyzed by RT-PCR and western blot and its distribution was
assessed by immunohistochemistry studies examined under confocal microscopy. Glaucomatous mice exhibited Ap4Avalues, which
changed in stimulated retinas as long as the pathology progressed varying from 0.73 ± 0.04 (3 months) to 0.170 ± 0.05 pmol/mg retina
(23 months). Concomitantly, NPP1 expression was significantly increased (82.15%) in the DBA/2J mice at 15 months. Furthermore,
immunohistochemical studies showed that NPP1 labeling was stronger in OPL and IPL labeling tangentially in the vitreal part of the
retina and was upregulated at 15months of age. Our findings demonstrate that Ap4A decreased levels may be related with exacerbated
activity of NPP1 protein in glaucomatous degeneration and in this way contributing to elucidate different mechanisms involved in
retinal impairment in glaucomatous degeneration.
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Introduction
Nucleotides are becoming relevant chemical messengers in
the physiology of the eye [1]. Apart from the more relevant
representative of nucleotides, ATP, others such as diadenosine
polyphosphates are becoming also significant since it partici-
pates in processes such as tear secretion, regulation of IOP, or
protection of the ciliary body from neurodegeneration [2, 3].
Diadenosine polyphosphates are structurally formed by
two adenosines bridged by a variable phosphate chain (from
2 to 7). The main representative of this family is diadenosine
tetraphosphate, abbreviated Ap4A [4, 5]. Diadenosine
polyphosphates are stored in synaptic vesicles, mainly stored
with monoamine and with acetylcholine and therefore their
exocytotic release can be achieved either by using agents such
as veratrine or 4-aminopyridine or simply by stimulating
nerve terminals with 59 mM KCl in the presence of extracel-
lular Ca2+ [6, 7]. Once at the extracellular milieu, diadenosine
polyphosphates interact with P2 purinergic receptors [6, 8],
and their actions are terminated by the action of ecto-
nucleotidases [9]. Most of these ApnA-hydrolyzing enzymes
display biochemical characteristics typical of members of the
ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP)
family. This group of ecto-enzymes is formed by seven mem-
bers termed NPP1-NPP7. All E-NPPs ecto-enzymes, but
NPP2, are type-II or type-I single-span transmembrane pro-
teins [9–11]. Among all, NPP1, NPP2, and NPP3 are capable
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of hydrolyzing diadenosine polyphosphates. In this
sense, they cleave these dinucleotides providing as products
AMP and adenosine 5′(n–1) phosphate, these three NPPs pre-
senting values of Km in the low micromolar range [12].
According to studies carried out in neural models, NPP1
seems to be the main ecto-nucleotidase cleaving diadenosine
polyphosphates [13, 14].
The presence and identification of nucleotides and dinucle-
otides in ocular secretions [15–17] in the neural retina [18, 19]
and their regulation by ecto-nucleotidases are indicating their
relevance in ocular physiology processes as previously
commented [2].
In the retina, the purinergic signaling system performs dif-
ferent roles in neuronal information processing [1]. The neural
retina, the retinal pigmented epithelium (RPE) and glial cells
express P1 (adenosine) and P2 (nucleotide) receptors [20] and
ecto-enzymes including NPP1 and NTPD2 inMüller cells and
ecto-ATPase located on photoreceptors, RPE, andMüller cells
[21–24]. Furthermore, purinergic signaling is activated in the
retina under pathophysiological conditions, which are mediat-
ing visual transduction and intracellular pathway cascades
leading to neurodegenerative processes in retinal cells
[25–29].
In this sense, the present work describes the changes in
Ap4A concentration and the increase in the expression of
NPP1 with the development of the glaucomatous pathology,
suggesting the possible role of these molecules in the physio-
pathology of this disease.
Materials and methods
Animals
The experiments were performed with female DBA/2J and
C57BL/6J mice for each stage of age, obtained from the
European distributor of Jackson Laboratories mice (Charles
Rivers Laboratories). C57BL/6J and DBA/2J mice were di-
vided in groups corresponding to different ages: 3, 9, 15, and
23 months of age. The total number of animals used for NPP
expression and Ap4A quantification was 15 animals per age.
All animal maintenance and experimental procedures were
in compliance with institutional, Spanish and European guide-
lines of animal care in the laboratory and animal research
(Guide for the Care and Use of Laboratory Animals), and
the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research. Animals were housed and handled with
the authorization and supervision of the Institutional Animal
Care and Use Committee from the Complutense University of
Madrid. Four mice were housed per cage in temperature and
light-controlled rooms maintained on a 12-h light/dark cycle,
and all animals had access to food and water ad libitum.
For immunohistochemical studies and sample collection of
mice retinas, animals were perfused with an i.p. injection of a
lethal dose of pentobarbital (Dolethal Vetoquinol®,
Especialidades Veterinarias, S.A., Alcobendas, Madrid, Spain).
IOP and electroretinogram measurements
IOP and electroretinogram (ERG) measurements were carried
out by anesthetizing the mice with an intraperitoneal (i.p.)
injection of ketamine (95 mg/kg, Imalgene 1000®, Merial,
Barcelona, Spain) and xylazine (5 mg/kg, Rompún®, Bayer,
S.A., Barcelona, Spain).
For IOP measurements, control and glaucomatous mice
were anesthetized and maintained on a warmed pad. The in-
traocular pressure was measured using a non-invasive re-
bound tonometer (Tonolab®; iCare Finland Oy, Helsinki,
Finland). Both eyes of each animal were measured immedi-
ately after anesthesia at 3, 9, 15, and 23 months, and IOP was
measured at the same time to avoid changes due to the circa-
dian rhythm.
For electroretinogram recordings the mice were dark-
adapted overnight before the ERG recordings. Pupil mydriasis
was induced by instilling 1% tropicamide (Colircusí
Tropicamida 1% ®; AlconCusí, S.A., El Masnou,
Barcelona, Spain) in the right eye of each mouse. Scotopic
threshold responses were recorded in response to light stimuli
produced signals generated in the retina were amplified
(1000×) and band filtered between 0.3 and 1000 Hz with a
Grass amplifier (CP511 AC amplifier, Grass Instruments,
Quincy, MA).
Electrical signals were digitized at 20 kHz using a Power
Lab data acquisition board (AD Instruments, Chalgrove, UK).
Light stimuli were calibrated periodically with a photometer
(Mavo Monitor USB, Gossen, Nürenberg, Germany). The
recordings were processed with the criteria established by
the International Society for Clinical Electrophysiology of
Vision (ISCEV).
The STR was analyzed for each stimulus, positive STR
(pSTR) was measured from the baseline to the peak of the
positive deflection, approximately 110–120 ms from the flash
onset, and the negative STR (nSRT) was measured from the
baseline to the peak of the negative deflection after the pSTR,
approximately 220 ms from the onset of the flash. ERG wave
amplitudes were analyzed for each animal group, and the per-
centage difference between the DBA/2J eyes and the control
eyes was obtained for each stimulus and was further averaged
(mean ± standard error of the mean, SEM).
HPLC measurements
Control and glaucomatous retinas at 3, 9, 15, and 23months of
age (n = 3 each group) were isolated under a stereo micro-
scope. Control samples of C57BL/6J and DBA/2J mice were
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maintained in Ringer solution (non-stimulated retinas) and the
stimulated retinas of DBA/2J mice and age-matched controls
were treated with 59 mM potassium chloride (KCl) in Ringer
solution for 1 min. The supernatants (1000 μl) were collected
in 1.5-ml tubes and maintained in ice during 5 min. The tubes
were heated in a 98 °C bath for 2 min and transferred to ice
10 min, to precipitate the proteins [30]. Then samples were
centrifuged at 22,000×g for 10 min at 4 °C to pellet the pro-
teins and maintained at freeze until high-pressure liquid chro-
matography (HPLC) analysis.
NPP1 activity was analyzed in glaucomatous mice model.
DBA/2J retinas at 3 and 15 months of age (n = 4 for each age)
were incubated in Locke’s solution (composition in mM:
NaCl, 140; KCl, 4.5; CaCl2, 2.5-, KH2PO4, 1.2; MgSO4,
1.2; glucose, 5.5; HEPES, 10; pH 7.4). Then, 10 μM
(250 pmol) Ap4A was added to the wells and retinas were
maintained at 37 °C in a humidified atmosphere containing
5% CO2. To assess Ap4A cleavage, samples of the incubated
mediumwere taken at different time points (t = 0 min, 15 min,
30 min, 1 h, 2 h) and the level of Ap4A was measured by
HPLC detection (see the next paragraph). Ap4Awas incubated
in parallel but in the absence of retinas as a negative control.
After thawing, levels of Ap4Awere analyzed in 1000 μl of
the supernatant using a reversed-phase HPLC equipped with
an isocratic pump (model 1515; Waters). The chromatograph-
ic conditions consisted of a C18 reverse-phase column,
250 mm length and 4.6 mm in diameter (Hyperchrome,
Scharlab). It was equilibrated with a mobile phase containing
10 mM KH2PO4, 2 mM tetrabutylammonium bisulfate
(TBA), and 20% acetonitrile adjusted to pH 7.5 with 5 M
KOH. The flow rate throughout chromatographic runs was
2 ml/min. Ap4Awas measured at 260 nm wavelength.
RT-PCR and quantitative real-time PCR
Total RNA from isolated retinas was extracted using RNeasy®
plus mini kit (Qiagen, Hilden, Germany), following the manu-
facturer’s instructions. After digestion with TURBO DNase
(Ambion, Austin, TX, USA), total RNAwas quantified and re-
verse transcribed using M-MLV reverse transcriptase, 6 μg of
random primers and 350 μM dNTPs (Invitrogen, San
Francisco, CA, USA). Quantitative real-time PCR (Q-PCR) re-
actions were carried out using LuminoCt® qPCR readymix
(Sigma-Aldrich), 5 μl of the RT product, and specific oligonu-
cleotide primers (all from Sigma-Aldrich) for ecto-nucleotide
pyrophosphatases/phosphodiesterases 1 and 3 (NPP1 and
NPP3, respectively) and for tissue non-specific alkaline phospha-
tase (TNAP), in combination with specific TaqmanMGB probes
(Roche, Basel, Switzerland). For NPP1, the primers used were
forward 5 ′-cggacgctatgattccttaga-3 ′ and reverse 5′-
agcacaatgaagaagtgagtcg-3′. For NPP3, the primers used were:
forward 5′-gatgcacaggacgaggagac-3′ and reverse 5′-
tgcacgtccatatttgagttg-3′. For TNAP, the primers used were
forward 5′-aatgaggtcacatccatcctg-3′ and reverse 5′-
cacccgagtggtagtcacaa-3′. The probes designed were FAM-5′-
gccaggaa-3′-MGB for NPP1, FAM-5′-ctgctggg-3′-MGB for
NPP3, and FAM-5′-ggatgctg-3′-MGB for TNAP. Fast thermal
cycling was performed using a StepOnePlus® Real-Time
System (Applied Biosystems, Foster City, CA, USA) as follows:
denaturation, one cycle of 95 °C for 20 s, followed by 40 cycles
each of 95 °C for 1 s and 60 °C for 20 s. The results were
normalized as indicated by parallel amplification of GAPDH
housekeeping gene. For GAPDH, commercial primers and
TaqMan MGB probe were supplied by Applied Biosystems.
Western blot
C57BL/6J and DBA/2J retinas (n = 5 mice for each stage of
age) were homogenized with a lysis buffer (50 mM HEPES,
pH 8, 150 mM NaCl, 1% NP-40 (w/v), 0.5% sodium
deoxicolate, 0.1% SDS and inhibitor proteases (1 mM
PMSF, 10 μg/ml leupeptin, 5 μg/ml pepstatin, 10 μg/ml
aprotinin, 1 mM sodium fluoride, and 2 mM sodium
orthovanadate) and were loaded, were subjected to 10%
SDS-PAGE, and were transferred to polyvinyldene fluoride
membranes using the Mini-PROTEAN Electrophoresis
System and the Mini Trans-Blot Electrophoretic Transfer
System (Bio Rad). Then were incubated overnight at 4 °C in
TBS1× 0.1% Tween 2-20 containing 5% non-fat milk
(blocking buffer) and monoclonal anti-NPP1 primary anti-
body (1:100; sc-166649, Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA). Finally, immunoreactive bands were
detected by chemiluminiscence using corresponding HRP
secondary antibody (1:10,000, Jackson ImmunoResearch)
and were studied to analyze the alterations in the expression
of NPP1 levels in the glaucomatous mice model during the
progress of the pathology and with respect to the aged
matched controls (3, 15, and 23 months). The densitometric
analysis was performed by using Kodak Molecular Imaging
Software (Kodak). The densitometry values of each sample
were normalized to the respective densitometric GAPDH
values.
Immunohistochemistry
DBA/2J mice at 3, 15, and 23 months (n = 3 mice at each time
point) were anesthetized and perfused transcardially with
phosphate-buffered saline (PBS) followed by a fixative solu-
tion of 4% paraformaldehyde in 0.1 M PBS at pH 7.4 at 4 °C.
The eyes were enucleated and dissected to avoid damaging
retina and were immersed in this solution for 1 h at 4 °C and
then washed in PBS before being cryoprotected in 10% su-
crose for 1 h and 30% overnight at 4 °C. Finally, the eyecups
were subsequently embedded in in tissue freezing medium
(Tissue-Tek© OCT) and 10-μm-thick retinal sections were
cut on a cryostat (Microm,Walldorf, Germany) in a horizontal
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plane and were collected on poly-L-lysine-coated slides and
stored at − 20 °C until use.
For immunofluorescence studies, sections were perme-
abilized with PBS-0.25% Tx-100 for 30 min, followed by
pre-incubation with the blocking solution, containing 10%
normal donkey serum (NDS; Jackson ImmunoResearch,
West Grove, PA, USA) and 0.1% Triton X-100 in PBS for
1 h at room temperature. Then, the slices were incubated with
goat polyclonal anti-NPP1 primary antibody (1:250; ab-
40003, Abcam, MA, USA) diluted in PBS-0.1% Tx-100 and
1% normal donkey serum overnight at 4 °C. Subsequently,
sections were washed in PBS-0.1% Tx-100 and incubated
with FITC-conjugated (green) donkey anti-goat IgG second-
ary antibody (Jackson ImmunoResearch, West Grove, PA,
USA) at a 1:200 dilution for 1 h, in darkness at RT. Finally,
the nuclei were stained with propidium iodide (red, Sigma-
Aldrich, St. Louis, MO) diluted 1:500 in PBS for 10 min and
sections were rinsed in PBS and mounted in fluoromount
Vectashield (Vector Laboratories, Palex Medical, Barcelona)
and coverslipped.
Microscope images were obtained with a confocal micro-
scope (Zeiss LSM 5 Zeiss Mikroskopie, Jena, Germany)
equipped with an argon laser (458/488/514 nm) and a
helium-neon laser (543 nm). Images were collected as 512–
512 pixels and projections of four frames using the single or
the multi-track scanning module. Images acquired were proc-
essed using the Adobe Photoshop 8.0 software (Adobe
Systems, Inc., San Jose, CA, USA).
Statistical analysis
Data were plotted as the mean ± standard error of the mean
(SEM). The results were analyzed using Graph Pad Instat®3
for Windows® (GraphPad Instat Software, San Diego, CA,
USA). Data were analyzed using unpaired t test for two-group
comparisons. A value of p ≤ 0.05 was considered statistically
significant.
Results
Extracellular Ap4A levels in stimulated
and non-stimulated retinas
In order to verify that the glaucomatous DBA/2J presented the
pathological changes due to the development of the glaucoma,
both IOP and ERG measurements were performed along the
whole study. In Fig. 1a, the changes in IOP in both control
(C57BL/6Jmice) and the glaucomatous (DBA/2J) animals are
shown. The IOP values remained stable in the control animals
along their life. On the contrary, in the DBA/2J there was an
elevation in IOP, which was maximal at 15 months of age
(11.5 ± 3.1 mmHg at 3 months vs. 31.3 ± 4.2 mmHg at
15 months, ***p < 0.001).
In the same way, the ERG patter along the pathology in the
DBA/2J mice was tracked. As presented in Fig. 1b, the pSTR
amplitudes showed significantly decreases at all tested light
stimuli, being maximal at − 3.0 log Cd.s.m−2 (46%).
Altogether, both IOP and ERG studies indicated that the
DBA/2J mice presented the expected features of the
glaucomatous pathology in this animal model.
The study on the presence of the dinucleotide Ap4A in the
retinas of both normal and glaucomatous mice depicted inter-
esting results. Extracellular Ap4A levels in control mice
(C57BL/6J) decreased with age between 3 and 23 months in
basal and stimulated conditions (Fig. 2a).
Fig. 1 Variations in the intraocular pressure (IOP) and electroretinogram
recordings in control and glaucomatous mice. a Measurements of
intraocular pressure in the control (C57) and glaucomatous (DBA/2J)
mice as a function of age. Significant differences were observed in
DBA/2J mice at 15 and 23 months of age when compared with the
3 months mice, which corresponds to the moment before the pathology
starts (***p < 0.001, *p < 0.05). b Scotopic threshold responses (STR)
from DBA/2J glaucomatous mice as a function of age. Between
3 months (before the pathology starts) and 15 months (when it is fully
established), it was possible to observe a statistically significant reduction
in the STR amplitudes when the animals presented the pathology (*p <
0.05. ***p < 0.001)
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The same stages of age were studied in DBA/2J mice to
assess Ap4A concentrations during the progression of the pa-
thology. The release of Ap4A from the retinas of
glaucomatous mice demonstrated a significant increase mea-
surable from 15 months (1.25 ± 0.30 pmol/mg retina) com-
pared to 23 months (2.98 ± 0.18 pmol/mg retina) in basal con-
ditions (*p < 0.05).
There were no significant changes in the stimulated Ap4A
levels at 3 and 15 months (1.57 ± 0.17 pmol/mg retina), in
contrast to that observed in Ap4A levels with age (3.15 ±
0.23 pmol/mg retina). Furthermore, Ap4A levels in
glaucomatous mice were significantly increased in stimulated
retinas compared to non-stimulated retinas (87%, *p < 0.05) at
3 months (Fig. 2b).
In addition, the net released Ap4Awas measured in control
mice and the levels remained constant during animal aging
(Fig. 3). Interestingly, in DBA/2J mice, the dinucleotide level
was strongly decreased between 3 and 23 months of age
respectively (from 0.73 ± 0.04 pmol/mg retina to 0.17 ±
0.05 pmol/mg retina).
Expression of NPP1 transcript is enhanced
in glaucomatous retinas at different stages of age
In a previous study, we reported the presence of ecto-
nucleotide pyrophosphatase/phosphodiesterase (NPPs) activi-
ty able to hydrolyze extracellular diadenosine polyphosphates
in neural cells. The expression of both NPP1 and NPP3 iso-
zymes was confirmed in neural cells, although diadenosine
polyphosphates hydrolysis was mainly mediated by NPP1
[14]. In order to analyze the presence of NPP1 and NPP3 able
to hydrolyze diadenosine polyphosphates in mouse retina,
both normal (C57BL/6J) and glaucomatous (DBA/2J) mice
were sacrificed at 3, 9, or 15 months of age and total RNA
from their isolated retinas was purified, retro-transcribed, and
quantified by Q-PCR. Moreover, the expression of a tissue-
Fig. 2 Ap4A release in control (C57) and glaucomatous (DBA) mice. a
Basal and KCl stimulated Ap4A release from whole mount retinas
obtained from C57BL/6J mice. Panel represents the mean of Ap4A
amounts at the given mice ages either under basal (blue circles) or
stimulated conditions (blue triangles). b Representative HPLC elution
profiles of basal (left panel) and stimulated (right panel) C57BL/6J
retinas. c Basal and KCl stimulated Ap4A release from whole mount
retinas obtained from glaucomatous DBA/2J mice. The panel represents
the mean of Ap4A amounts at the given mice ages either under basal (red
circles) or stimulated conditions (red triangles). d Representative HPLC
elution profiles of basal (left panel) and stimulated (right panel) DBA/2J
retinas. Results are the mean ± SD of three independent experiments (*p
< 0.05)
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non-specific alkaline phosphatase, able to hydrolyze a wide
spectrum of extracellular nucleotides but not dinucleotides,
was also analyzed [31]. As shown in Fig. 4, the expression
of NPP1, NPP3, and TNAP was detected in retina from both
normal and glaucomatous mice, TNAP transcript being the
most abundant one, followed by NPP1 and to a lesser extent
NPP3 (comparison of normalized ratios versus GAPDH
housekeeping transcript). Interestingly, the expression of
NPP1 was significantly increased in mice glaucomatous ret-
inas compared to control ones at all ages analyzed (Fig. 4a).
On the contrary, no differences were observed in the expres-
sion on either NPP3 or TNAP ecto-enzymes (Fig. 4b, c, re-
spectively). Moreover, whereas NPP1 expression was main-
tained invariable for 3 to 15 months old in control retinas, an
upregulation of NPP1 was observed in glaucomatous retinas
from older mice, suggesting that NPP1 and, consequently,
extracellular dinucleotide levels could be specifically involved
in the development of glaucomatous phenotype.
Alterations of NPP1 protein levels in glaucomatous
mice model
In order to quantify possible ecto-nucleotide pyrophosphatase
changes, NPP1 expression was analyzed by western blot
(Fig. 5a, b). NPP1 is weakly expressed in DBA retinas at
3 months and its expression was increased at 15 months
(82.15%, **p < 0.01). In older glaucomatous mice, it was pos-
sible to see a reduction when comparing with DBA/2J at
15 months. To further determine the differences with respect
to the matched controls, NPP1 was evaluated and the results
were significantly increased at 3 months (92.45%, *p < 0.05)
and 15 months (94.65%, *p < 0.05).
The activity of this enzyme cleaving Ap4A in animals be-
fore (3 months of age) and after glaucoma appears (15 months
of age) was measured during 120min. As it can be seen in Fig.
5c, the cleavage of Ap4A by NPP1 in the 3-month-old retinas
only permitted the detection of 123.1 ± 20.3 pmol of this di-
nucleotide after 2 h of incubation with the retinas (n = 4).
Interestingly, when the same experiment was performed with
the glaucomatous retinas (15 months old), the remaining
Ap4A was 26.6 ± 15.4 pmol (n = 4). Ap4A in the absence of
any tissue (control) was hydrolyzed very slowly (Fig. 5c).
Furthermore, immunohistochemistry studies were ana-
lyzed to identify possible alterations in the distribution of
ecto-nucleotidase activity during the progress of
glaucomatous impairment. NPP1 immunoreactivity was de-
tected in the outer plexiform layer (OPL) and inner plexiform
layer (IPL) in control and pathological retinas. At 15 months,
when the retinal dysfunction was observed in a previous study
[32], NPP1 immunoreactivity was increased in DBA/2J mice.
On the contrary, as shown in Fig. 6, the expression of de ecto-
nucleotidase protein was reduced in the pathological mice at
23 months compared to 15 months. This localized retinal
immunolabeling with NPP1 suggesting the relevant role of
these proteins in the synaptic connectivity through the plexi-
form layers.
Discussion
Diadenosine polyphosphates (ApnA) are molecules that act
via P2 receptors to serve as neuromodulators [6, 33, 34] and
contribute to several physiological and physiopathological
mechanisms in the nervous system [35–38]. Besides, these
signaling molecules are involved in numerous ocular physio-
logical processes including tear secretion, corneal wound
healing, retinal detachment, or intraocular pressure regulation
[39–41]. Dinucleoside polyphosphates are in the modulation
of retinal processing via P2 receptors after being released from
nerve endings [19, 42, 43]. For this reason, the assessment of
extracellular concentrations reached by Ap4A and other nu-
cleotides could be a relevant feature since these compounds
could play an important function during the visual impairment
in glaucomatous damage. In this sense, it is very interesting to
indicate that Ap4A basal concentration at 23 months of age
was statistically higher than the measured in the previous
stages (see Fig. 1). The reason for such an increase is not clear,
although some ideas can be suggested. The dinucleotide Ap4A
has been claimed as an Balarmone.^ An alarmone is a mole-
cule whose concentrations increase as a consequence of envi-
ronmental changes [44]. It could be the case that the variations
in the retinal environment due to glaucoma pathology may
trigger the production of this dinucleotide. This makes sense
since Ap4A has also been described as a molecule that protects
the eye’s neural structures [33] and in the same way it could be
Fig. 3 Net stimulated Ap4A release in both control (blue triangles) and
glaucomatous (red triangles) mice followed from 3 and 23 months. The
net stimulated release of Ap4A was obtained in each stage of age by
subtracting basal release from 59 mM KCl stimulated release. Values
are the mean ± SD of eight experiments (**p < 0.01, ##p < 0.01, ###p <
0.001)
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also protecting the retina. Nevertheless, these ideas deserve
further research to be confirmed.
Considering these findings, extracellular dinucleotide levels
and their suitable regulation by degradation mechanisms, in-
volving ecto-nucleotidase activity, suggest an important point
to consider in the maintenance of the extracellular medium.
Ecto-nucleotidases comprise a relevant family of proteins in-
volved in the regulation of nucleotide-dependent signaling in
the nervous system as previously noticed [9–13, 45, 46].
Previous studies demonstrated increased levels of these
nucleotides in aqueous humor and other anterior ocular struc-
tures in glaucomatous patients [40, 47, 48]. In accordance
with these reports, ATP and Ap4A concentrations were in-
creased in the aqueous humor (J. Pintor, personal communi-
cation) of DBA/2J mice, a well-characterized model of glau-
coma [18]. Furthermore, relevant changes in nucleotide levels
were observed in murine retinas during glaucomatous degen-
eration [19, 49] and in DBA/2J mice.
In this study, stimulated Ap4A concentration was dra-
matically reduced in the glaucomatous mice from 3 to
23 months of age whereas dinucleotide levels in the con-
trol mice remain constant, suggesting a potential implica-
tion of ecto-nucleotidase activity in the pathology devel-
opment. Indeed, at 23 months of age both, basal and
stimulated Ap4A levels, were very close each other. This
is probably indicating that the cell damage that occurs at
this stage of the pathology is producing a non-controlled
release of this dinucleotide. Also, it is important to bear in
mind that the reduction in the released Ap4A may be a
consequence of the increased expression of other enzymes
such as TNAP which could partially eliminate it from the
extracellular milieu (Fig. 4). It is clear that the reason for
such lack of release of Ap4A is a complex subject that
demands further studies. Ap4A net release levels observed
in glaucomatous retinas could be indicating the loss of the
potential neuroprotective effect of this compound with ag-
ing in relation to the observed results in ciliary processes
[33] and central nervous system [50]. Furthermore, al-
though biological properties of dinucleotides remain un-
known, some authors have described the potential
therapeutical role of Ap4A in retinal impairments [51,
52] and brain injury mediated by inhibition of apoptotic
process [50, 53].
Due to the presence of changes in Ap4A concentrations
during retinal degeneration, the activity of ecto-nucleotidases
was evaluated at different ages to analyze their involvement in
the regulation of Ap4A levels in the extracellular milieu. Our
data suggest that a reduction of extracellular Ap4A may con-
tribute to protection against retinal injury through exacerbated
ecto-nucleotidase activity leading to the concomitant ATP
Fig. 4 Normalized expression of ecto-nucleotidases NPP1, NPP3, and
TNAP transcripts in glaucomatous versus control retinas at different
ages. Retinas from C57BL/6J and DBA/2J mice at 3, 9, and 15 months
of age were isolated and total RNAwas extracted and retro-transcribed.
NPP1 (a), NPP3 (b), and TNAP (c) mRNAs were quantified by Q-PCR,
using GAPDH as housekeeping gene. Results are mean ± s.e.m. of three
independent experiments in triplicate. *p ≤ 0.05, ***p ≤ 0.001 (unpaired t
test)
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Fig. 6 Immunohistochemical localization of NPP1 in glaucomatous
retinas. Vertical sections at 3 months in the control C57BL/6 mice (a)
and 3, 15 and 23 months of central retinas from DBA/2J mice (b–d).
NPP1 staining (green) showed a significant increment in DBA/2J mice
retinas at 15 months (c) with respect to 3 months (b) and 23 months (d).
Nuclei were stained with a nuclear marker (propidium iodide; red). All
images were collected from the central area of the retina. ONL, outer
nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer;
IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar, 20 μm
Fig. 5 NPP1 expression and activity in the glaucomatous and control
retinas with aging. a A representative western blot of NPP1 (≈
105 kDa) levels in C57BL/6J and DBA/2J mice at 3, 9, 15, and
23 months. GAPDH (37 kDa) levels are shown as a loading control. b
Western blot analysis of NPP1 at 3, 9, 15, and 23 months of age. Values
are the mean ± SD of five independent experiments (**p < 0.01). c Study
on the degradation of Ap4A for 2 h assayed on 3- and 15-month-old
retinas as described in the BMaterials and methods^ section. Control
trace corresponds to Ap4A incubated in the absence of any retina.
Values are the mean ± SD of four independent experiments
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release. This is an important aspect to take into account since
the generated ATP consequent to the Ap4A cleavage by NPP1
and NPP3 can activate P2X receptors. This triggers different
physiological processes (Fig. 7), including apoptotic
signalways through P2X7 receptors stimulation, mainly in
the retinal ganglion cells [31, 54, 55].
The second aim of the study was to analyze the expression
of the main ecto-enzymes involved in the degradation of
dinucleonucleotides: the ecto-nucleotide pyrophosphatase
(E-NPP) [12] family and tissue-non-specific alkaline phos-
phatase (TNAP), the latter is unable to cleave Ap4A since it
can only act on nucleotides with 5′ phosphate ends [56].
NPP1, NPP3, and TNAP transcripts have been quantified in
glaucomatous and control mice retinas by quantitative real-
time PCR in other neuronal populations [14]. Interestingly,
the current results showed a significant upregulation of
NPP1 in mice glaucomatous retinas and are in agreement with
immunoblot, histochemical, and hydrolysis studies. In this
sense, it was relevant to see that the presence of NPP1 at
3 months of age was able to cleave 50.8% of the incubated
Ap4A in 2 h, while in the case of the 15-month-old
glaucomatous retinas, the percentage of Ap4A degradation
was 89.4%. These two values were consistent with the
NPP1 expression observed in the western blots where the
bands intensity at 15 months of age doubled the intensity of
the 3 months old.
It is interesting to see that although the glaucomatous mice
develop the pathology from the sixth month of age, it was
possible to see significant differences with the control animal
from 3 months old. These differences became more robust
when the animals developed the pathology. This may suggest
that the C7BL/6J micemight not be the best control animal for
some studies and in this sense, several functional studies sug-
gest significant differences in the C57BL/6J strain with re-
spect to the glaucomatous mouse [57]. This is one of the
reasons why age-dependent studies in DBA/2J mice were
imperative.
The neural retina expresses the activity of various ex-
tracellular nucleotide-degradative enzymes showing spe-
c i f i c immuno labe l ing fo r the ec to -nuc l eo t ide
pyrophosphatase 1 (NPP1) along the retina. Vertical sec-
tion analysis revealed that NPP1 distribution is observed
in retinal plexiform layers, suggesting their implication
in visual information modulation.
Both extracellular Ap4A degradation and the increase of
NPP1 expression could contribute to retinal impairment in
glaucomatous damage. Exacerbated NPP1 activity during
the progression of the pathology may explain the diminished
dinucleotide extracellular levels. It is worthy to note that the
activity of the enzyme NPP3 needs to be taken into consider-
ation. This enzyme hydrolyzes Ap4A at the same rate as NPP1
does [11]; nevertheless, its expression is far lower that NPP1
(see Fig. 4). We estimate that more than 90% of the dinucle-
otide cleavage is due to mainly to NPP1.
Further investigations are necessary to confirm the involve-
ment of extracellular nucleotide and NPP1 expression in the
main neuronal populations responsible for the modulation of
synaptic transmission and in the major glial component of the
retina, the Müller cells [21, 24]. Double immunolabeling ex-
periments should be also necessary to co-localize NPP1 ex-
pression with different markers could reveal roles in the axon
synaptic terminals and optic nerve fiber layer of the retinal
circuitry.
Considering the results presented and recent studies in
our group, nucleotide and dinucleotide levels and purinergic
signaling are contributing to the modulation of the visual
function in DBA/2J mice [58]. ATP levels and the vesicular
nucleotide transporter (VNUT) were increased in
glaucomatous mice when the retinal degeneration was de-
veloped (at 15 months), and this suggests that the exacer-
bated degradation of this signaling molecule in other nucle-
otides diminishes Ap4A levels during the progression of the
pathology through hydrolytic activity of ecto-nucleotidases
[18]. The NPP1 increase may be in part responsible for the
reduced Ap4A concentrations in the retina of aged DBA/2J
mice. Furthermore, dinucleotide alterations in concentration
were accompanied by an increase in intraocular pressure
and a loss of retinal function in this model [32, 59, 60].
The present manuscript supports a previous work showing
altered purinergic signaling in chronic glaucoma [49] by
adding the involvement of the dinucleotide Ap4A to that
of the ATP.
Fig. 7 The possible connection between Ap4A, NPP1, and glaucoma.
The increase in expression in both plexiform layers permits the action
of the enzyme cleaving the dinucleotide to produce ATP. This ATP
generated in the inner plexiform layer can stimulate the P2X7 receptors
present in the retinal ganglion cells triggering an apoptotic process that
will conduct cell death
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In summary, we have demonstrated that Ap4A levels and
NPP1 ecto-enzyme were altered during the progress of the
pathology. Increased levels of NPP1 in DBA/2J has been de-
tected at 15 months of age concomitant with decreased Ap4A
release that could be associated with retinal impairment, sug-
gesting a novel pharmacological approach.
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